As the WHO delayed clearance for Covaxin seeking more technical details, the All India Peoples Science Network said it was a serious setback to India’s plans to distribute the vaccine to other countries and to those travelling abroad who took Covaxin.
In a statement on Wednesday, AIPSN referred to its earlier call for disclosure of Covaxin’s trial data and said serious damage was done to India’s reputation by this flawed application to the WHO regulators “which has also besmirched the standing of Indian science and regulatory systems, which will now come under heightened international scrutiny and suspicion”.
“BB applied to DCGI for EUA with grossly inadequate data from clinical trials inviting rejection, followed by behind-the-scenes arm twisting by government which resulted in the grant of EUA. More detailed results of Phase-3 clinical trials were then released by BB in instalments, interim results two months later and complete trial data in June 2021,” stated AIPSN.
It said despite criticism from scientists and others, Bharat Biotech was yet to publish results in a peer-reviewed journal after posting just a pre-publication paper.
It urged Centre, ministries and departments to adhere to scientific standards for conduct and analysis of clinical trial results, publication of results as peer-reviewed articles and complete transparency.